Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Total Liabilities (2020 - 2025)

SAB Biotherapeutics' Total Liabilities history spans 6 years, with the latest figure at $21.3 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 16.95% year-over-year to $21.3 million; the TTM value through Dec 2025 reached $21.3 million, up 16.95%, while the annual FY2025 figure was $21.3 million, 16.95% up from the prior year.
  • Total Liabilities reached $21.3 million in Q4 2025 per SABSW's latest filing, up from $18.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $42.6 million in Q4 2021 to a low of $7.9 million in Q1 2021.
  • Average Total Liabilities over 5 years is $19.0 million, with a median of $18.2 million recorded in 2023.
  • The largest YoY upside for Total Liabilities was 245.4% in 2022 against a maximum downside of 53.4% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $42.6 million in 2021, then tumbled by 53.4% to $19.8 million in 2022, then soared by 34.24% to $26.6 million in 2023, then crashed by 31.59% to $18.2 million in 2024, then rose by 16.95% to $21.3 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Total Liabilities are $21.3 million (Q4 2025), $18.4 million (Q3 2025), and $18.1 million (Q2 2025).